You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses and Publications

Congress Materials

Access abstracts, posters, and presentations presented at the following congresses

September 2020

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2020 (Virtual)

Abstracts

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non‑small cell lung cancer (NSCLC): a phase 3 trial in progress Phase 3 trial in progress: tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma Phase 3 trial in progress: tislelizumab vs placebo in combination with concurrent chemoradiotherapy (cCRT) in patients with localized esophageal squamous cell carcinoma (ESCC) Platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with extensive-stage small cell lung cancer: A phase 3 trial in progress RATIONALE 304: tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line (1L) treatment for advanced squamous non‑small cell lung cancer (sq NSCLC) Tislelizumab + chemotherapy versus placebo + chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer: a phase 3 trial-in-progress Tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC) Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
September 2020

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2020 (Virtual)
June 2020

American Association for Cancer Research (AACR)

June 2020

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2020 (Virtual)
May 2020

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 2020 (Virtual)

Abstracts

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC) Phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL) Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study
May 2020

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)


Most Recent Publications

 Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

Search Publications and Congress Materials

This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.

BeiGene, Ltd. maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeiGene’s written permission.  
 
This is an online medical resource for scientific and clinical information. BeiGene makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.